Lockhart CM - Search Results

1

The landscape of real-world evidence of rituximab utilization and clinical outcomes in patients with cancer, rheumatoid arthritis, and multiple sclerosis: A scoping review.

Li KH, Kaker M, Lau J, Noonan K, Zhang S, McDermott CL, Lockhart CM. Li KH, et al. Among authors: lockhart cm. J Manag Care Spec Pharm. 2024 May;30(5):480-489. doi: 10.18553/jmcp.2024.30.5.480. J Manag Care Spec Pharm. 2024. PMID: 38701025 Free PMC article. Review.

2

Utilization, user characteristics, and adverse outcomes of insulin glargine originators and follow-on drug in patients with diabetes in the United States.

Rai A, Nam YH, Mendelsohn AB, Marshall J, McDermott CL, Toh S, Lockhart CM. Rai A, et al. Among authors: lockhart cm. J Manag Care Spec Pharm. 2023 Jul;29(7):842-847. doi: 10.18553/jmcp.2023.29.7.842. J Manag Care Spec Pharm. 2023. PMID: 37404073 Free PMC article.

3

Real-world switching and discontinuation outcomes of infliximab biosimilars in patients with rheumatoid arthritis: A scoping review.

Yin Y, McDermott C, Lockhart C. Yin Y, et al. J Manag Care Spec Pharm. 2023 Sep;29(9):985-998. doi: 10.18553/jmcp.2023.29.9.985. J Manag Care Spec Pharm. 2023. PMID: 37610110 Free PMC article. Review.

4

Outpatient directly observed therapy for hepatitis C among people who use drugs: a systematic review and meta-analysis.

McDermott CL, Lockhart CM, Devine B. McDermott CL, et al. Among authors: lockhart cm. J Virus Erad. 2018 Apr 1;4(2):118-122. J Virus Erad. 2018. PMID: 29682305 Free PMC article.

5

Utilization patterns and characteristics of users of biologic anti-inflammatory agents in a large, US commercially insured population.

Mendelsohn AB, Nam YH, Marshall J, McDermott CL, Kochar B, Kappelman MD, Brown JS, Lockhart CM. Mendelsohn AB, et al. Among authors: lockhart cm. Pharmacol Res Perspect. 2021 Feb;9(1):e00708. doi: 10.1002/prp2.708. Pharmacol Res Perspect. 2021. PMID: 33372729 Free PMC article.

6

Patient Characteristics and Utilization Patterns of Short-Acting Recombinant Granulocyte Colony-Stimulating Factor (G-CSF) Biosimilars Compared to Their Reference Product.

Mendelsohn AB, Marshall J, McDermott CL, Pawloski PA, Brown JS, Lockhart CM. Mendelsohn AB, et al. Among authors: lockhart cm. Drugs Real World Outcomes. 2021 Jun;8(2):125-130. doi: 10.1007/s40801-021-00228-9. Epub 2021 Jan 30. Drugs Real World Outcomes. 2021. PMID: 33517548 Free PMC article.

7

Identification of cancer chemotherapy regimens and patient cohorts in administrative claims: challenges, opportunities, and a proposed algorithm.

Lockhart CM, McDermott CL, Mendelsohn AB, Marshall J, McBride A, Yee G, Li MS, Jamal-Allial A, Djibo DA, Vazquez Benitez G, DeFor TA, Pawloski PA. Lockhart CM, et al. J Med Econ. 2023 Jan-Dec;26(1):403-410. doi: 10.1080/13696998.2023.2187196. J Med Econ. 2023. PMID: 36883996 Free article.

8

Barriers and facilitators to conduct high-quality, large-scale safety and comparative effectiveness research: The Biologics and Biosimilars Collective Intelligence Consortium experience.

Lockhart CM, McDermott CL, Felix T, Lin ND, Cziraky MJ, Mendelsohn AB, Brown JS. Lockhart CM, et al. Pharmacoepidemiol Drug Saf. 2020 Jul;29(7):811-813. doi: 10.1002/pds.4885. Epub 2019 Aug 11. Pharmacoepidemiol Drug Saf. 2020. PMID: 31402533 No abstract available.

9

BBCIC Research Network Analysis of First-Cycle Prophylactic G-CSF Use in Patients Treated With High-Neutropenia Risk Chemotherapy.

Pawloski PA, McDermott CL, Marshall JH, Pindolia V, Lockhart CM, Panozzo CA, Brown JS, Eichelberger B. Pawloski PA, et al. Among authors: lockhart cm. J Natl Compr Canc Netw. 2021 Aug 16:jnccn20268. doi: 10.6004/jnccn.2021.7027. Online ahead of print. J Natl Compr Canc Netw. 2021. PMID: 34399406

10

Incidence of Serious Infections and Design of Utilization and Safety Studies for Biologic and Biosimilar Surveillance.

Zhang J, Sridhar G, Barr CE, Eichelberger B, Lockhart CM, Marshall J, Clewell J, Accortt NA, Curtis JR, Holmes C, McMahill-Walraven CN, Brown JS, Haynes K. Zhang J, et al. Among authors: lockhart cm. J Manag Care Spec Pharm. 2020 Apr;26(4):417-490. doi: 10.18553/jmcp.2020.26.4.417. J Manag Care Spec Pharm. 2020. PMID: 32223608 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

26 results

Search Page